TuHURA Biosciences, Inc./NV
Close on Oct 19, 2026
- Market cap
- $113.86M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 1, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | Apr 1, 2025 | Before market open | – | – | – |
| Q4 FY2023 Ended Jun 30, 2023 | Sep 18, 2023 | After market close | – | – | – |
| Q3 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | $-1.94 | – |
| Q2 FY2023 Ended Dec 31, 2022 | Feb 14, 2023 | After market close | – | $-2.10 | – |
| Q1 FY2023 Ended Sep 30, 2022 | Nov 9, 2022 | After market close | – | $-0.07 | – |
| Q4 FY2022 Ended Jun 30, 2022 | Sep 27, 2022 | Before market open | – | – | – |
| Q3 FY2022 Ended Mar 31, 2022 | May 13, 2022 | Before market open | – | – | – |
Press releases
Announcements TuHURA Biosciences filed with the SEC
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K/A
TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Executive or director change · Other events · EX-99.1 to Form 8-K
TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.3 to Form 8-K
TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
TuHURA Biosciences Completes Acquisition of Kineta
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Enters into $12.5 Million Equity Financing Transaction and Receives Additional
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides a Corporate Update
Results of operations · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
IFx Technology Innate Immune Agonists Designed to Overcome Primary Resistance to Checkpoint Inhibitors
Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics
Material agreement · Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
TUHURA MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Material agreement · Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Material agreement · Acquisition or disposition completed · Results of operations · Executive or director change · Charter or bylaw amendment · Other events · EX-99.4 to Form 8-K
Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kintara Therapeutics Announces Record Date for CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
TUHURA BIOSCIENCES, INC. AND SUBSIDIARY
Other events · EX-99.1 to Form 8-K
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
Other events · EX-99.2 to Form 8-K
Kintara Therapeutics Announces Fiscal 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
It is imperative for ALL stockholders to VOTE your shares.
Regulation FD disclosure · EX-99.1 to Form 8-K
Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with
Regulation FD disclosure · EX-99.1 to Form 8-K
Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
It is imperative for ALL stockholders to VOTE your shares.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
200 Broadacres Drive, 3rd Fl.
Regulation FD disclosure · EX-99.2 to Form 8-K
It is imperative for ALL stockholders to VOTE your shares.
Regulation FD disclosure · EX-99.3 to Form 8-K